Esperion Therapeutics (NASDAQ:ESPR), the pharmaceutical company focused on lipid-management therapies, reported total revenue of $168.4 million for the fourth quarter, representing a 144% increase over the same period last year.
The quarterly performance capped a year of significant expansion, with full-year 2025 revenue reaching $403.1 million, a 21% rise year-over-year.
The explosive quarterly growth was driven in large part by collaboration revenue, headlined by a $90 million payment from partner Otsuka.
Domestically, Esperion saw consistent traction for its product portfolio, with U.S. net product revenue climbing approximately 38% for the full year to $159.6 million.
Despite the top-line growth, the company reported a net loss of $22.7 million for the fiscal year as it continues to invest in market access and clinical development.
In a move to diversify its cardiovascular pipeline, Esperion announced a definitive agreement to acquire Corstasis and its lead candidate, Enbumyst™.
The company also highlighted strengthened patent settlements and expanded payer coverage, which are expected to streamline the commercial path for its non-statin cholesterol treatments.
Esperion ended the year with a cash balance of $167.9 million.
Looking ahead, management provided 2026 operating expense guidance in the range of $225 million to $255 million.